Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib

© 2023. Springer Nature Limited..

Although the rapid onset of effect of glucocorticoids (GCs) allows rapid control of rheumatoid arthritis (RA) symptoms, their chronic use may be associated with several adverse events. The 2022 update of EUALR recommendations for the management of patients with RA suggests to reduce and discontinue oral GCs as quickly as possible. Considering GCs as a "bridging therapy" to promptly reduce symptoms and control inflammation, fast-acting drugs such as tofacitinib could allow faster and safer tapering of GCs. The purpose of this pilot study was to evaluate the steroid-sparing effect of adding tofacitinib in patients with RA inadequately responsive to methotrexate taking concomitant GCs. In this open-label pilot study, we enrolled patients with moderate to severe RA on a stable dose of prednisone (5-12.5 mg/day) who started treatment with tofacitinib. After 1 month, in patients who achieved at least a moderate EULAR response (decrease of > 1.2 in DAS28_CRP), GCs was tapered according to a predetermined schedule until complete discontinuation at week 12. Disease activity was assessed after 4, 12, 24 and 48 weeks of treatment. The primary endpoint was the percentage of patients discontinuing GCs after 12 weeks of tofacitinib treatment. We enrolled 30 patients (26 F: 4 M, mean age 60 ± 13 years, mean disease duration 13.2 ± 7.8 years). The primary endpoint was achieved: 9 patients (30%) discontinued GCs at week-12. At week-24, other 12 patients (46%) withdrew GCs. The median prednisone dose decreased from 5 mg/day (interquartile range 5-10 mg) to 2.5 (0-5) mg/day at week 12 and 48 (p < 0.00001 vs baseline). At week 48, 12 out of 30 patients (40%) had discontinued prednisone. The percentage of patients achieving remission or low disease activity increased throughout the follow-up without any difference between patients who discontinued or not the GC. In this cohort of long-standing RA patients treated with tofacitinib, the discontinuation of glucocorticoids was achievable in up to 30% of patients. These results should encourage rheumatologists to consider GCs tapering and discontinuation of GCs, as suggested by the 2022 EULAR recommendations, an achievable goal.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:13
Enthalten in:	Scientific reports - 13(2023), 1 vom: 20. Sept., Seite 15537

Sprache:	Englisch

Beteiligte Personen:	Spinelli, Francesca Romana [VerfasserIn] Garufi, Cristina [VerfasserIn] Mancuso, Silvia [VerfasserIn] Ceccarelli, Fulvia [VerfasserIn] Truglia, Simona [VerfasserIn] Conti, Fabrizio [VerfasserIn]

Links:	Volltext

Themen:	87LA6FU830 Glucocorticoids Journal Article Prednisone Research Support, Non-U.S. Gov't Tofacitinib VB0R961HZT

Anmerkungen:	Date Completed 22.09.2023 Date Revised 19.11.2023 published: Electronic Citation Status MEDLINE

doi:	10.1038/s41598-023-42371-z

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM362275815